Moxe Health streamlines the bi-directional exchange of clinical data between health plans and provider systems.
The company provide solutions for risk adjustment, HEDIS and Star ratings, claims denial management, HCC reconciliation, patient summary, ADT notifications, and care gap management. Plans seamlessly send back data and insights while never straying from clinicians’ EHR workflows.
Moxe’s clinical data clearinghouse allows health plans to easily receive information from health systems. Health plans can then seamlessly send back data and insights. With automated solutions for risk adjustment, quality, and care management programs, Moxe facilitates access to the information essential to your success in the market shift to value-based care.
Moxe’s neutrality in providing data connectivity lets you realize the full potential of your existing investments in population health, quality, and analytics solutions.
Apella is a technology company that brings modern engineering to improve surgery. It was founded in 2020 and is headquartered in San Francisco, California.
Cleerly is a healthcare company focused on improving the prevention of heart attacks through innovative digital care pathways. It aims to establish a new standard for coronary artery disease by combining advanced clinical science with cutting-edge artificial intelligence. Cleerly's platform offers a non-invasive approach that quantifies and characterizes plaque buildup in coronary arteries, enhancing the understanding of cardiovascular health. By providing actionable clinical insights, the company enables healthcare providers to better identify at-risk patients and implement early treatment strategies. Ultimately, Cleerly's data-driven solutions aspire to deliver significant value to the healthcare system while improving heart health outcomes for individuals susceptible to heart attacks.
GPB Scientific, LLC is a biotechnology company based in Richmond, Virginia, that specializes in developing a liquid biopsy platform aimed at isolating viable circulating tumor cells from blood samples. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating and enriching rare tumor cells while removing red blood cells and normal white blood cells. GPB Scientific markets its innovative technology to life sciences companies and research institutions, supported by a substantial portfolio of patents related to microchip technology for cell capture and enrichment. Established in 2002, GPB Scientific continues to advance its contributions to cancer diagnostics and research.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Spyglass Ophthalmics, Inc. is a company focused on developing ophthalmic therapeutic devices aimed at enhancing vision and eye care for patients. Founded in 2019 and based in Mission Viejo, California, Spyglass addresses unmet needs in areas such as cataract treatment, lens replacement, and other chronic ophthalmic conditions. By creating innovative devices, the company seeks to provide patients with quality eye treatment that is also affordable.
Relievant Medsystems, Inc. is a medical device company focused on developing innovative treatments for chronic axial low back pain. The company's primary offering is the Intracept procedure, which targets the basivertebral nerve to relieve vertebrogenic low back pain through a minimally invasive approach. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional development and operations office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic options that enhance the quality of life for patients suffering from this prevalent condition.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries.
The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
GPB Scientific, LLC is a biotechnology company based in Richmond, Virginia, that specializes in developing a liquid biopsy platform aimed at isolating viable circulating tumor cells from blood samples. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating and enriching rare tumor cells while removing red blood cells and normal white blood cells. GPB Scientific markets its innovative technology to life sciences companies and research institutions, supported by a substantial portfolio of patents related to microchip technology for cell capture and enrichment. Established in 2002, GPB Scientific continues to advance its contributions to cancer diagnostics and research.
Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.
Vesper Medical, Inc., a medical device company, develops minimally invasive peripheral vascular products. It offer Vesper DUO Venous Stent System, built for venous stenting. The company was founded in 2016 and is based in Wayne, Pennsylvania.